

		Mean	Median (Range)	N	%	n/a (%)
Demographic data	Age (years)	52	53 (21-73)	66		
	Age, men (years)	51	51 (26-71)	26	39	
	Age, women (years)	52	54 (21-73)	40	61	
Asthma	Age at onset (years)	34	33 (3-66)			2 (3)
	Years with phenotype	17	15 (1-48)			
	Set as first diagnosis			38	58	
	Control of disease: good or very good			55	83	3 (5)
	Control of disease: poor or very poor control			8	12	3 (5)
	Positive family history			37	56	8 (12)
	Negative family history			21	32	8 (12)
Nasal polyps	Age at onset (years)	36	34 (11-70)			1 (2)
	Years with phenotype	16	12 (1-45)			
	Set as first diagnosis			10	15	
	Surgical removal of nasal polyps			63	95	
	Control of disease: good or very good			38	58	3 (5)
	Control of disease: poor or very poor control			25	38	3 (5)
	Positive family history			14	21	11 (17)
	Negative family history			41	62	11 (17)
NSAID intolerance	Age at onset (years)	35	35 (5-65)			6 (9)
	Years with phenotype	16	15 (0-46)			
	Set as first diagnosis			7	11	
	NSAID-related symptoms			64	97	2 (3)
	ASA challenge			30	45	
	ASA desensitization			23	35	
	Successful ASA desensitization			12	18	
	Positive family history			6	9	20 (30)
	Negative family history			40	61	20 (30)
Treatment	Inhaled corticosteroids			62	94	
	Leucotriene modifiers			28	42	
	Biologic medical therapy			2	3	
	Topical nasal steroids			59	89	
	Regular peroral ASA 250 mg			5	8	
	Peroral corticosteroids for asthma †			42	64	3 (5)
	No peroral corticosteroids needed for asthma †			21	32	3 (5)
	Peroral corticosteroids for nasal polyps †			39	59	10 (15)
Ear symptoms	No peroral corticosteroids needed for nasal			17	26	10 (15)
	Control of disease: good or very good			48	73	8 (12)
	Control of disease: poor or very poor control			10	15	8 (12)
	No hearing aid			57	86	5 (8)
	Bilateral hearing aid			4	6	5 (8)